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Abstract Urothelium, a specialized epithelium, covers the
urinary tract and act not only as a barrier separating its light
from the surrounding tissues, but fulfills an important role in
maintaining the homeostasis of the urothelial tract and well-
being of the whole organism. Proper function of urothelium is
dependent on the precise assemble of highly specialized gly-
coproteins called uroplakins, the end products and differenti-
ation markers of the urothelial cells. Glycosylation changes in
uroplakins correlate with and might reflect progressive stages
of pathological conditions of the urothelium such as cancer,
urinary tract infections, interstitial cystitis and others. In this
review we focus on sugar components of uroplakins, their
emerging role in urothelial biology and disease implications.
The advances in our understanding of uroplakins changes in
glycan moieties composition, structure, assembly and expres-
sion of their glycovariants could potentially lead to the devel-
opment of targeted therapies and discoveries of novel urine
and plasma markers for the benefit of patients with urinary
tract diseases.
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Urothelium is a multilayer epithelium of the inner surface of
the mammalian urinary bladder which extends from the renal
pelvis to the urethra. It is composed of three to six layers of
heterogeneous epithelia cells at different stages of differentia-
tion, that contain basal, intermediate and umbrella cells
(Fig. 1a) [1–3]. Urothelium is an unusual epithelial tissue
because of stratified complex of cellular layers with intimate
connections to neural and connective tissue elements [4, 5]. The
mammalian urothelium apical surface is in 90 % covered by
urothelial plaques [6] forming the membrane interdigitation at
the cell borders [7]. This interdigitation creates a membrane
zipper, likely contributing to the barrier function of the
urothelium [2, 7]. The urothelial plaques or “asymmetric unit
membrane” (AUM) (Fig. 1b) are constructed by uroplakins
(UPs) (Fig. 1c), the markers of the advanced degree of the
differentiation stage of umbrella cells [reviewed in [5, 8–11].
In mammals characterized by a thicker layer of the urothelium
(e.g., humans), UPs are mostly present on the cell surface, in
mammals with thinner urothelium (e.g. rodents), they can be
also found in the deeper layers of the tissue [12]. UPs are highly
tissue-specific, but in mice, some of their isoforms have been
also identified in the mammary gland, pancreas, lung and heart
[11]. Studies using transgenic models for UP and models with
inactivated genes for these proteins provided important data
regarding their function. Variation in their normal expression
leads to a variety of urinary disorders such as vesicourethral,
interstitial cystitis (IC), overactive bladder, hydronephrosis or
renal dysfunction and renal failure [6, 11, 13, 14].
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UPs, including immature form of UPII, are glycoproteins
which are inextricably linked to their function. Disorders in
normal glycosylation of UPs lead to abnormal epithelial ad-
hesion, leakage of the urinary tract, increased tumor cell
invasiveness and spread of Escherichia coli (E. coli) infection
[15, 16]. However, little is known and understood how qual-
itative and quantitative changes in their sugar structures may
influence pathological conditions of the urothelium. In depth
knowledge of UPs glycosylation malfunctions might find
applications in early diagnosis and targeted treatments of
urinary tract pathologies. Presented review brings this fasci-
nating but yet unexplored area in urothelium research.
Uroplakins are the main structural components
of urothelium
AUM of all mammalian urinary bladder comprises four major
UPs: UPIa and Ib, UPII, and III, which form a unique crys-
talline 2D array of 16-nm particles covering almost the entire
polarized urothelial surface (Fig. 1) [17]. UPI a and Ib (27-
kDa and 28-kDa, respectively) belong to the tetraspanin fam-
ily. Their rod-shaped structures have four closely packed
transmembrane helices (Fig. 2) spanning the membrane and
extending into the extracellular loops, capped by a disulfide-
stabilized head domain [18, 19]. In contrast, UPII and III (15-
kDa and III 47-kDa, respectively) cross the membrane only
once and their single transmembrane domain (Fig. 3) share a
stretch of ~12 amino acid residues on the extracellular side [5,
8, 9, 20–22].
UPs are synthesized as monomers, however they undergo a
dynamic and highly regulated assembly process, which begins
in the endoplasmic reticulum (ER) where UPIa with UPII and
UPIb with UPIII form specific cross-linked heterodimers [5,
8, 23, 24]. Formation of the UPIa/II and UPIb/IIIa heterodi-
mers is a prerequisite for UPs to exit ER [24]. That stage of
heterodimer formation seems to be functionally important as
the ablation of UPsII or IIIa genes abolishes urothelial plaque
formation and compromises their function [6, 13, 25]. How-
ever, Tu et al., [24] reported that UPIb can exit ER without a
heterodimeric complex formation. In a post-Golgi compart-
ment, UPs heterodimers form increasingly larger crystalline
arrays. Two heterodimers bind to a heterotetramer through
tight interactions of the transmembrane domains as well as
the extracellular domains, so that the head domains of their tall
partners can bridge each other at the top (Fig.1b). At turn, the
interactions between the complexes and the tertiary interaction
between the 16-nm particles contribute to the formation of UP
tetraspanin structural/signaling networks. The aggregated UP
complexes are sorted at the trans-Golgi network (TGN) into
destined vesicles, which subsequently cover almost all mature
fusiform vesicles in cytoplasm. These organelles migrate to-
wards the apical cell surface where they fuse with the plasma
membrane. By consequence, almost the entire apical
urothelial surface is covered by 16-nm particles of urothelial
plaques composed of UPs hexagonally packed into unique
paracrystalline array [8, 18, 23, 26, 27]. The unique
Fig. 1 Scheme of the urothelium
and uroplakin plaque
composition. Urothelium is
composed of three layers: a basal
cell layer attached to a basement
membrane, an intermediate layer,
and an apical layer with large
hexagonal cells known as
umbrella cells (a). The apical
surface of umbrella cells creates a
unique asymmetric unit
membrane (AUM) composed of
hexagonal plaques with six
tetramers where two dimers
UPIa/II and Ib/IIIa are linked (b).
High-mannose N-glycan (light
gray circle) on UPIa and complex
N-glycans (dark gray circle) on
UPIb and IIIa are depicted.
Mature UPII lacks sugar moieties
(c). Drown based on [22, 46]
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architecture of the hexagonal urothelial plaques with the dis-
tinctive cellular interconnections are critical for tightness,
integrity and proper function of the urothelium [2, 5, 6, 11,
28, 29]. Little is known about the molecular events governing
fusiform vesicles trafficking into the luminal surface and their
incorporation into apical surface. Some molecules, such as a
myelin-and-lymphocyte protein (MAL) expressed by T lym-
phocytes, myelin-forming cells, and polarized epithelial cells
Fig. 2 Sugar moieties on UPIa
and Ib. UPIa and Ib possess four
transmembrane domains (TD)
(shown as cylinders) containing
conserved aa residues. TD1 and
TD2 are connected via a small
extracellular loop (EC1), and TD3
and TD4 via a large extracellular
loop (EC2). The main
glycovariant of UPIa contain a
high-mannose glycan linked to
Asn-169 (a), whereas UPIb has a
tetraantennary fucosylated
complex glycan linked at Asn-
131 (b). Abbreviations: Asn
asparagine; Gal galactose;
GlcNAc N-Acetylglucosamine;
Fuc fucose; Man mannose
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were reported to facilitate the incorporation of exocytic
uroplakin-delivering vesicles into the apical membrane of
urothelial umbrella cells [26, 27, 30–32].
UPs are tissue-specific molecules, but some of their iso-
forms have been also identified in other organs. For example
in mice they have been found in the mammary gland, pancre-
as, lung and heart [11]. Adachi et al. [33] reported that UPIb is
expressed in several non-urothelial epithelia, such as the cor-
neal epithelium.
N-glycans of UPs, O-glycoproteins and proteoglycans
form urothelial glycocalyx
Urothelium is highly glycosylated tissue with luminal surface
covered by glycocalyx composed of proteoglycans, N- and O-
glycoproteins including secretory mucins. Quantitative anal-
ysis of the sialic acid, uronic acid, and hexosamine contents of
delipidated rabbit bladder mucosa revealed a larger proportion
of sialoglycoproteins as compared to glycosaminoglycans
(GAG) [34].
The degree of glycosylation and microheterogeneity of the
urothelium glycoproteins were reported to be associated and
dependent on the origin of the species, the particular distribu-
tion in the multilayers of the urothelium, and the stage of the
maturation and differentiation of urothelial cells. Using peanut
agglutinin and Vicia villosa lectin as well as specific mono-
clonal antibodies, Vinter-Jensen and Ørntoft. [35] showed
the presence of T and Tn antigens and mucin -type glycopro-
teins on murine and porcine urothelial tracts [35]. The expres-
sion of T and Tn glycotops on urothelium has been upregu-
lated after stimulation of cell layers lining the urinary tract
with epidermic growth factor (EGF) [35]. So far, certain
mucins, such as MUC1 (epitectin) and proteoglycans, such
as syndycan-1 have been isolated and characterized [36, 37].
As shown by Higuchi et al. [38] the rabbit mucins and glyco-
proteins of urothelium surface layers consisted of weakly
sialylated and neutral oligosaccharides O-glycosidically
linked to serine and threonine residues. In addition, the deeper
layers of the rabbit urothelium (e.i., lamina propria and muscle
layer) are rich in GAGs, mainly hyaluronates and chondroitin
sulfates, which presence on the surface of the urothelium are
Fig. 3 The dynamic
glycosylation modifications
during maturation of UPII. UPII
is synthesized as a precursor
prepropeptide (a). Cleavage of the
signal peptide facilitates N-
glycosylation of the propeptide by
high-mannose glycans (b). The
synthesis of preproUPII and
signal peptide cut off take place in
ER. In GA two of the three high-
mannose N-glycans of the
proUPII are transformed into
complex glycans (c). Cleavage of
the glycosylated propeptide
occurs in TGN (d). The mature
UPII lacks asparagine and thus
sugar moieties (e). Abbreviations:
ER endoplasmic reticulum; GA
Golgi apparatus; TGN trans-Golgi
network, 1-3- N-glycosylation
sites. Drown based on [22]
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negligible [38]. By lectin-histochemistry, Desantis et al., [39]
characterized sialylated O-linked glycans expressed on don-
key (Equus asinus) urothelium. These glycans contained ter-
minal or internal mannoses, and typical secretory moieties of
sialylated O-glycoproteins (sialylated galactose and disaccha-
ride composed of galactosamine-galactose). Expression of
sialic acid on glycoproteins might indicate that the urothelium
is not simply a inert barrier but can modulate the composition
of soluble urinary proteins, which may play pathophysiolog-
ical roles in the lower urinary tract [39]. Several urothelium-
derived glycoproteins have been detected in urine of cows [1],
rabbits [34, 36], pigs [40], rats [35] and people [37, 40, 41].
Using glycoproteomic technique Halim et al. [41] character-
ized 53 N-and O- glycoproteins out of 2,800 proteins present in
human urine. They depicted 58 N- and 63 O- glycan profiles
and urine complex type glycoproteins have been found to be
sialylated and fucosylated bi- and multi- branched [41].
Closely related and conservative in their structure, trans-
membrane UPs types Ia/Ib (25-kDa/27-kDa), IIIa/IIIb (45-
kDa/35-kDa) and immature form of UPII are N-
glycoproteins [42, 43]. Their N- linked complex type oligo-
saccharides elicit microheterogenity. Thus, UPs can exist in
several glycoforms, such as a high-mannose, bi- and/or more
branched glycans, which could be further sialylated and/or
fucosylated [42].
The function of urothelium glycoproteins can be related to
those ascribed generally to the glycoproteins, and specific to
the tissue. In the urothelium, their function is bound to the
protection of membrane components from digestion by hy-
drolases, particularly present in the urine [40], participation in
intercellular signaling, cell adhesion and recognition, selective
permeability of molecules across the blood – urine barrier [1,
4, 10, 40, 44] and inhibition or promoting of bacterial coloni-
zation [42, 45]. There is some experimental evidence that
unique architecture of urothelial plaques and function are
strictly dependent of the UP glycosylation [5, 6, 15, 16, 21,
22].
Glycosylation of UPIa and UPIb differs markedly
UPIa and Ib (25 and 27-kDa) are members of the tetraspanin
family of glycoproteins with four transmembrane domains
(TD 1–4) creating minor and larger loops, where the latter is
stabilized by three disulfide bridges [19]. Both UPs are closely
related, rich in charged amino acids approx. 40 % identical [4,
22, 46, 47]. Sugar parts of UPs Ia and Ib are located in the
extracellular portion of their top surface (Fig. 2) exposed to the
urothelium, in the hydrophilic larger loop connecting 3 and 4
TD domains [8].
In the 90s of the last century, based on data obtained by
UPs N-glycosidase digestion it was assumed that both UPs: Ia
and Ib on their extracellular surface domains carry high-
mannose N-glycans, which protect protein part from digestion
by proteases [8, 46, 48]. However, in 2001 Zhou et al. [14]
reported that mouse UPs Ia and Ib, despite their identity in
amino acid sequence, are glycosylated differently, and only
UPIa harbors terminal mannose moieties, whereas the UPIb
does not [14]. In 2006 Xie et al. [42] using more advanced
techniques (permethylation of released glycans by in-gel gly-
cosidase and protease digestion and mass spectrometric tech-
nique) confirmed that each of UPIs has only one potential N-
glycosylation site. Mouse UPIa (25-kDa) possesses a glycan
attached to Asn at 169 aa sequence position (Asn −169)
(Fig. 2a) and UPIb (27-kDa) at 131 (Asn −131) (Fig. 2b).
Murine and human UPIa are highly mannosylated with six to
nine molecules of terminal mannose residues attached to N-
acetylglucosamine core part (Man6GlcNAc2 and
Man9GlcNAc2) (Fig. 2a) [42]. The predominant (43 %) mu-
rine glycovariant of UPIa contains eight terminal mannoses,
whereas other glycoforms terminated by 7, 9 and 5 mannoses
represent 28%, 24% and 5%, respectively. In contrast, mouse
UPIb is multi-antennary complex type oligosaccharide rich in
fucoses (Fig. 2b). The fucosylated tetra-antennary N-
glycoform is the main mouse UPIb glycovariant. A high-
mannose variant of UPIb with 6 mannose residues and/or
the hybrid type were found to be rare and constitute only
6 % to 15 % of UPIb [42].
The UPIa interact with the immature form of UPII
(proUPII, i.e. containing a prosequence) whereas UPIb with
UPIIIa forming UPIa/UPII and UPIb/UPIIIa heterodimers,
respectively. That stage of dimer formation is important and
facilitate their ER exit [22, 24, 49, 50]. Xie et al., [42]
suggested that the drastically different carbohydrate process-
ing of UPIa and UPIb proteins may reflect differences in their
folding, masking and the interactions with associated proteins.
The differences might be related to differences in accessibility
of nascent proteins to glycosylation and/or alternatively to
heterodimer formation. The initial step of N-glycosylation, a
co-translational process is identical for both proteins i.e., the
transfer of an N-glycan precursor, Glc3Man9GlcNAc2, from
lipid-linked dolichol to a protein glycosylation site. The sub-
sequent trimming of the precursor by alpha-mannosidases in
ER and addition of other sugar moieties by glycosyltransfer-
ases in the Golgi complex [51, 52] vary significantly for UPIa
and UPIb depending on peptide folding and accessibility of
the glycosylation sites to glycosylating enzymes [42]. On the
other hand, an alternative interpretation by Xie et al. [42] is
that the prosequence portion of pro-UPII upon binding to its
partner UPIa in ER can block UPIa’s single glycan from
further trimming by the sugar-modifying enzymes.
It has been reported that mannosylated oligosaccharide part
of UPIa can serve as the receptor for the FimH lectin adhesin
of type 1-fimbriated E. coli, the bacteria that causes a great
majority of urinary tract infections [11, 14, 42, 53]. This topic
will be discussed in chapter below.
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Differentiation-dependent glycosylation of UPII
Based on sequence analysis of cDNA/gen and mRNA trans-
lation it has been established that UPII is primarily synthe-
sized as a 19-kDa non-glycosylated prepro-UPII precursor
(Fig. 3a). It comprises three parts of linked sequences: 1) a
N-terminal 26–28 amino acids fragment (2-kDa), 2) a middle
fragment located at 59 amino acids propeptide with three
asparagines, the potential sites for N-glycosylation, and 3) a
100 amino acids polypeptide (15-kDa) corresponding to the
mature native form of UPII [8, 20, 48]. The prepro-UPII
precursor undergoes dynamic glycosylation modifications
differentiation-dependent [5, 54], resulted probably from dif-
ferent participation of cellular glycosyltransferases [55]. In ER
the signal sequence is cut-off from the 19-kDa prepro-UPII
precursor. A propeptide is further glycosylated by addition of
three attached high-mannose N-glycans. The attachment of
sugar chains to pro-UPII causes an increase in the molecular
weight of the immature form of UPII to 29-kDa (Fig. 3b).
Further increase of molecular mass of proUPII to 32-kDa is
associated with the transformation of two out of three
high-mannose glycans into complex glycans (Fig. 3c) [5,
22, 24, 54]. Next, in TGN the glycosylated peptide is cut-off
from pro-UPII (Fig. 3d) and mature form of UPII is created.
The precursor of bovine pro-UPII which carries complex N-
glycans does not contain exposed sites susceptible for degra-
dation by exoproteases, but has four furino-like
endoproteases. For efficient cleavage, the furin-cleavage site
requires some arginines in signature sequence: Arg−4-Xaa−
3-(Lys/Arg)−2-Arg−1 [56]. The released mature bovine UPII
(15-kDa) does not possess the asparagines/s able to be N-
glycosylated [20]. The mature UPII bound with a cell has a
long extracellular domain of 71 amino acids, a transmembrane
domain of 25 amino acids, and short intracellular domain [8,
20, 48]. It has been suggested that the furin-mediated cleavage
of the glycosylated prosequence of UPII plays a role in regu-
lating the assembly of UP to form AUM [22].
An analogous scheme for maturation of UPII was reported
for UPII of nearly all mammals with the exception of mouse
UPII where propeptide possesses one potential glycosylation
site [48]. However, there is no data on whether mature form of
mouse UPII expresses or not oligosaccharide parts.
The pro-UPII by itself cannot exit ER unless is stabilized
by partner’s UPIa. [22, 24]. The glycosylation alternations are
responsible for conformational changes in pro-UPII that allow
heterodimer formation. According to Hu et al., [22], the high-
mannosyl-glycans on pro-UPII appear only in ER and later,
the mannosylated glycans are further processed in Golgi net-
work. In consequence two of them become the antennary
complex type oligosaccharides. Moreover, Hu et al., [57]
indicated that the prosequence of UPII requires a proper
disulfide linkage in order to maintain hairpin-like proUPII
conformation which facilitate binding to UPIa and the
formation of the proUPII/UPIa complex. It has been reported
that the induced conformational changes allow UPIa/proUPII
complex to exit ER and facilitate further proUPII maturation
[5, 22, 24, 54]. Hu et al. [22] hypothesized that a special,
complex glycan-forming glycosyltransferase in superficial
umbrella cells might be involved in producing AUM-
associated 32-kDa pro-UPII, which in turn can promote the
binding of two partner’s heterodimers (UPIa-UPII and UPIb-
UPIII) to form a heterotetramer.
The exclusive expression of all high-mannose glycans on
pro-UPII, and lack of the antennary complex N-glycans, can
exclude a heterotetramer formation and finally can cause a
lack of AUM on the surface of umbrella cells [22]. Moreover,
the high-mannose N-glycans of pro-UPII participate in
preventing the crystalline plaques assembly in undifferentiat-
ed intermediate cells of urothelium [22]. Interestingly, the
differentiation-dependent glycosylation of pro-UPII does not
occur in cultured bovine urothelial cells, and the synthesized
UPs do not assemble into crystals in cultured cells [54].
UPIII comprises a large N-linked oligosaccharide moiety
UPIII (UPIII 47 to 49-kDa) is a single, typical integral trans-
membrane glycoprotein with three potential N-glycosylation
sites (Fig. 4) and cysteine residues on N-terminal extracellular
domain (189 amino acids). UPIII carbohydrates significantly
contribute to the surface glycocalyx [9]. Charged residues of a
shorter, C-terminal cytoplasmic part of UPIII (52 amino acids)
have multiple potential phosphorylation sites. Deglycosyla-
tion and cDNA sequencing revealed that UPIII contains a
large N-linked oligosaccharide moiety of up to 20-kDa at-
tached to a 28-kDa-core protein.
The composition of sugar part of UPIII is species depen-
dent. The polypeptide part of bovine UPIII consists of 287
amino acids (28.9-kDa), and its large sugar moiety constitute
more than 40 % of the total mass of the whole molecule [9,
48]. This sugar moiety is larger than glycans expressed by
other uroplakins. The deglycosylation of bovine glycoprotein
by specific N-glycosidase F (PNGase F) and O- glycosidase
digestions indicates that UPIII contains N-linked glycan/s and
lacks O-linked glycan/s [9]. Based on cDNA sequence anal-
yses, Wu and Sun [9] hypothesized that UPIII sequence
contains four potential N-glycosylation sites. They pointed
out three N-glycosylation sites at Asn34, Asn74, and
Asn170 [9]. They also suggested that the glycosylation at
Asn34 is questionable because of a proline [9]. So far, there
is no experimental data showing which of predicted glycosyl-
ation sites are truly glycosylated. Malagolini et al. [58]
showed that N-oligosaccharides of bovine UPIII can be ter-
minated by sialic acid α(2-3)- and α(2-6)-linked to Gal(1-4)-
GlcNAc-sequence, however some other glycovariants may
contain the terminal Galα(1-3)-Gal epitope formed by
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galactose residue α(1-3)-linked to the Galβ(1-4)-GlcNAc unit
of antennary N-glycan (Fig. 4). The occurrence of the Galα(1-
3)-Gal epitope on N-glycans in UPIII is species specific and
such epitope is absent on UPIII and other human N-glycopro-
teins. Enzyme α1,3-galactosyltransferase is not expressed in
humans, apes and Old-World monkeys where the gene is
inactivated through frame shift and nonsense mutations [58].
Hu et al., [6] reported that the UPIII ablation leads to the
overexpression, defective glycosylation, and abnormal
targeting of UPIb. Interestingly, also UPII ablation leads to a
similar up-regulation of the UPIb mRNA level and its
hypoglycosylation suggesting that UPIb changes represent a
general response to a perturbed uroplakin assembly [13]. The
UPIII-depleted urothelium features small plaques, becomes
leaky, and has enlarged uretheral orifices resulting in the back
flow of urine, hydronephrosis, and altered renal function
indicators. Deng et al., [50] reported that in the cases of UPIII
ablation, UPI is able to form a dimer with a novel 35-kDa
urothelial plaque associated glycoprotein (p35) that is closely
related to UPIII [50]. The synthesis of UPIII-related glycopro-
tein is most likely up-regulated as a compensatory mechanism
in the case of UPIII absence. The UPIII-related glycoprotein
and UPIII have a similar overall type 1 transmembrane topol-
ogy. Their amino acid sequences are 34 % identical, share an
extracellular juxtamembrane stretch of 19 amino acids and the
both UPIII isoforms form a heterodimer with uroplakin Ib, but
not with any other UPs. Deng et al., [50] devided p35 UP into
uroplakin IIIa (47–49-kDa) and IIIb (35-kDa). In spite of fairly
low levels of UPIIIb (10 % of UPIIIa), its interaction with
UPIb in ER is believed to be an important early step in
urothelial plaque assembly [50]. It has been found that UPIIIb
is expressed in urothelial tumors of the urinary bladder in cows
that had suffered from chronic enzootic hematuria for several
years [59]. Given the fact that the protein parts of the UPIIIa
and IIIb have similar molecular masses (approximately
30-kDa), both isoforms of UPIII can differ in the content of
glycosylated and/or phosphorylated residues attached [50].
Recent work by DeSalle’a et al. [60] concerning the diver-
gent evolution of uroplakin, indicated the existence of addi-
tional mammalian isoform - UPIIIc. According to the authors,
the UPIIIc amino acid sequence is 37 % identical to a protein
part of UPIIIb and like two other UPIII isoforms can form
heterodimers with UPIb. In contrast to other UPIIIs, UPIIIc
isoform does not have a ~20 aa region between the
Fig. 4 Hypothetical
glycosylation of UPIIIa. UPIIIa is
highly glycosylated and possess
complex N-glycans (blue circles).
Bovine UPIII N-glycans may
contain Sia linked to Gal via
α(2-3)- or α(2-6)-glycosidic
bonds. Cellular signaling occurs
via phosphorylation of the UPIIIa
cytoplasmic tail. Drown based on
[9] and [58]
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transmembrane domain and the N-terminus of the protein
[60]. So far, nothing is known about glycan moiety structure
of UPIII isoforms other than UPIIIa.
Mannose residues on UPIa are pivotal for urinary tract
E.coli infection
Urinary tract infection involving E. coli constitutes 90% of all
infections of this system and the second most common in the
human population infectious disease with high treatment costs
[53, 61, 62]. Infection is initiated by attaching bacteria to the
normally sterile uroepithelium via a lectin- type 1-fimbriae
(FimH) adhesins of E.coli to urothelial surface receptor UPIa,
rich in mannose residues [14, 63, 64]. The reaction is specific
for E. coli expressing adhesins H -type, and not E. coli with
other types of adhesins or bacteria lacking fimbria [42, 65].
Effective interaction of FimH with UPIa may also cause
infections of the upper part of the urinary tract including
kidneys since expression of UPIa has been also found in the
ureters and renal pelvis [66–68]. In these locations a signifi-
cant role in bacterial adhesion is attributed to fimbriae P
expressed by certain strains of E. coli causing pyelonephritis
[69]. Malagolini et al. [58] reported that initiation of infection
in cows is also possible via E. coli strains expressing S-type
fimbriae able to recognizeα(2-3)-sialylated glycans expressed
by bovine α2,3-sialylated UPIII glycovariant. After success-
ful invasion, uropathogenic bacteria replicate, invade
neighbouring cells, and mature into dense, biofilm-like inclu-
sions. Within the bladder epithelium bacteria can survive for
months and are responsible for treatment- challenging recur-
rent urinary tract infections [53, 63, 64].
Group of Wu et al. [45] for the first time showed that type
1-fimbriated E. coli binds to bovine urothelial plaque proteins
via UPIa. Later, in view of significant differences in the
glycosylation between UPIa (high mannosylated glycan) and
UPIb (almost exclusively complex-type glycan), the former
one has been recognized as responsible for E. coli infections
[14, 42, 70, 71]. The multimannosylated glycoforms of UPIb
present in minute quantities are buried deeply in the structural
pocket and are not available for bacterial adhesins [42].
The urothelial receptor on UPIa for bacterial adhesin FimH
was localized byMin et al. [71] on the six inner domains of the
16 nm urothelial plaque particle. FimH adhesin has a mannose-
binding pocket that is capable at pH 4–9 of specific reactionwith
glycoproteins with exposed mannose residues [14, 70, 71].
FimH binding with UPIa occurs with a moderate strength
(Kd ~100 nM), but a multiple binding sites present on the
bacteria and multiple array of polymerized UPs receptors,
makes the attachment relatively strong [14]. Wellens et al.,
[63] reported that FimH interacts with Manα(1-3)Manβ(1-
4)GlcNAcβ(1-4)GlcNAc in an extended binding site. The in-
teractions along the α(1-3) glycosidic bond and the first β(1-4)
linkage to the chitobiose unit are conserved with those of FimH
with buty α-D-mannose. The strong stacking of the central
mannose with the aromatic ring of Tyr48 is congruent with
the high affinity found for synthetic inhibitors in which man-
nose is substituted by an aromatic group [63].
The adhesion of uropathogenic E. coli to highly
mannosylated UPIa is only an initial step of subsequent events
in the pathogenesis of urinary tract infections [64, 72, 73].
Studies of Wang et al., [64] indicated that the interaction of
lectin-mediated adhesion with the urothelial UPIa can further
induce cellular signaling by phosphorylation of the UPIIIa
cytoplasmic tail and leads to cytoskeletal rearrangements
and further bacterial invasion. They showed by cryo-electron
microscopy that FimH binding to the extracellular domain of
UPIa induces global conformational changes and movements
in all UPs transmembrane helices. Downstream signaling
events can be initiated by lateral translocation of the UP
cytoplasmic tails [64]. Thumbikat et al. [73] further discov-
ered that equally important to efficient insult by E. coli and
bacterial adhesion is the UPIIIa cytoplasmic tail phosphoryla-
tion on a specific threonine residue by casein kinase II,
followed by an elevation of intracellular calcium. Moreover,
the same group [72] utilizing in vitro models of urothelial
differentiation, demonstrated that E. coli mediated cell-death
is entirely dependent on the proper differentiation of UPIII and
directly correlated with its enhanced maturation. Thus, during
the urinary tract infections where superficial urothelial cells
are damaged and less differentiated cells are exposed,
urothelial apoptosis is reduced [72]. Further, Klumpp et al.
[74] using a murine model of urinary tract infection showed
that urothelial apoptosis is a key event in the pathogenesis
mediated byE.coli and requires both caspase-dependent direct
induction of the extrinsic pathway and caspase 8-mediated
Bid cleavage -dependent indirect intrinsic pathway [74].
Against excessive colonization by microorganisms, AUM
is protected by glycocalyx formed of glycosylated UPs [5, 10,
75]. Experimental work by Geerlings et al. [76] showed that
people with diabetes are more prone to urinary tract infections
compared to healthy people. It is therefore suggested that
disorders in glycosylation of UPs found for example in dia-
betes, may have a significant role in the development of
urinary tract infections, especially in their recurrent and per-
sistent form [15, 77]. Like diabetes, bacterial adhesion facili-
tates transportation of immatured mannosylated glycoproteins
to the surface [16]. It has been proven that the expression
profile of sugar residues expressed by UPs is more important
for the epithelial adhesion of microbes than the variations of
an individual determinant of bacterial adhesin [78].
Attempts to block interactions between bacterial adhesins and
sugars exposed by UPs are of great importance for unraveling
the extremely important clinical issue related to bacterial infec-
tions of urothelium. It should be noted that the physiological
concentrations of naturally occurring mannosylated glycoprotein
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present in urine (Tamm - Horsfall protein) are able to inhibit
adhesion of bacteria and serve as a first line of defense against
infection [79, 80]. In recent years, many new revolutionary
antibacterial agents that effectively eliminate urinary tract infec-
tion have been designed. A particularly promising class of drugs
include remedies that inhibit bacterial adhesion to urothelial cells
i.e. FimH antagonists for example in the form of vaccines,
which, by their mechanism of action minimize bacterial drug
resistance [81–84]. Design of FimH antagonists, precisely glyco-
agonists are based on the imitation of natural sugar epitope
structures [63, 83, 85]. Recently, Schwardt et al. [51] attempted
to create new FimH antagonists on the structure of triazoles
with mannose residues. In other work, in vitro and in vivo studies
showed that a protein D present on the surface of the mucous
membranes of various organs for example in lungs, has the
ability to bind directly to UPIa and block bacterial adhesion to
the urothelium [86]. Preventing and treating of urinary tract
infections is one of the most important priority of modern
medicine because of the universality and continuous increase
in the incidence of this medical condition.
Impairment of the mucosal glycoconjugates in IC
An impairment of the mucosal glycoconjugates could be an
important factor in the development of bladder disorders such
as interstitial cystitis (IC). The disease is characterized by
increased permeability of urothelial membrane, influx of urine
into underlining tissues, lower back pain and frequent, urgent
and painful voidings [29]. Epidemiological studies indicate
that this disease is much more common than recognized
clinically. A number of theories have been created to explain
the etiology of IC and the data cited by various authors are
sometimes contradictory [87, 88]. One of the most important
and most popular theories proposed by Parsons is the concept
of increased permeability of the urothelium to harmful sub-
stances in the urine that are linked to quantitative and qualita-
tive changes in the layer of GAGs [89]. Parsons et al. showed
reduced secretion of GAGs and one of their metabolite -
uronic acid in urine of IC patients as compared to control
group [90]. The observations made using a scanning electron
microscope confirmed the reduction in the GAG layer and
leakage of urothelial membrane. The concept of increased
permeability of urothelial cells was further supported by find-
ings of Fowler et al., which revealed in patients the presence
of Tamm-Horsfall protein deposits [91]. Later, Neal et al.
established the presence of antibodies against Tamm-
Horsfall protein in the patient serum [92]. The majority of
patients demonstrated qualitative changes of proteoglycans
[88]. These findings again underline a crucial role for the
proper composition of glycovariants and precise glycosylation
of the urothelium in the function and physiological condition
of the urothelial tract.
Glycosylation changes in urothelial cancer
Cancer derived from the urothelium is the sixth most common
type of cancer in the world. About 90–95 % of cases occur in
the bladder, the remaining involve the ureter and renal
collecting system (about 5–10 %). In cancer, the cancer-
associated carbohydrate structures are reported to play key
roles in cancer progression by altering the cell-cell and cell-
environment interactions. As a consequence of neoplastic
transformation the cell membrane glycoconjugates undergo
characteristic changes [93, 94]. UPs create attractive
urothelium tumor markers due to the high conservation of
their structure and selective tissue specificity. However, it
seems somewhat paradoxical that their expression does not
exactly correlate with the degree of differentiation of cancer
and they might be found even in metastatic tumors despite the
fact that they are final differentiation products of normal
urothelial cells [49, 95]. On the other hand, exploration of
the differentiation–dependent glycosylation of uroplakins
might shed the light on this conundrum.
So far little is known how glycosylation changes correlate
with dedifferentiation of cancer cells, the stage and progres-
sion of the disease [16]. Pode et al. [96] showed that expres-
sion of Lewis X glycoantygen detected on the umbrella cells is
associated with bladder cancer with specificity of 86.4 %. The
tumor-associated carbohydrate, an antigen sialyl-Tn (STn)
and its major biosynthetic enzyme, the sialyltransferase
(sT6), highly expressed by several human carcinomas and
preneoplastic lesions [93] have been reported to be expressed
by tumors of the bladder [97, 98]. Ferreira et al. [97] showed
that 75 % of the high-grade bladder tumours, presenting
elevated proliferation rates and high risk of recurrence/pro-
gression, expressed STn glycotope. The antigen STn has not
been found in the normal urothelium, but was mainly
expressed in non-proliferative areas of the tumour invading
the basal andmuscle layers as well in tumour-adjacent mucosa
suggesting a tumor field effect. Furthermore, the data of Lima
et al. [98] strongly suggested that Bacillus Calmette–Guerin
(BCG) immunotherapy is efficient against STn - and s6T-
positive tumours. Further authors proposed that expressions
of that glycoantigen and its related enzyme may be used as
independent predictive markers of BCG treatment response
and in the identification of patients who could benefit from
this immunotherapy. Recently, Zupančič et al. demon-
strated in rodents a modified expression of species-
dependent sugar moieties during carcinogenesis [16].
Using lectin-immunohistochemical analysis they showed
in vivo and ex vivo that rodent neoplastic urothelium
displayed higher reactivity with Jacalin (lectin from
Artocarpus integrifolia) as compared to normal tissue. Unlike
in mouse carcinogenesis model, in rat model the decreased
binding to another natural Amaranthus caudatus lectin was
noted. Moreover, in normal urothelium, terminally differentiated
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umbrella cells expressed all four UPs, which were present in the
large urothelial plaques covering mature fusiform vesicles and
the apical plasma membrane. In contrast, the preneoplastic
urothelium contained poorly differentiated cells with microvilli
and small, round vesicles that were uroplakin-negative and no
urothelial plaques were observed in these cells [16].
UPII and particularly UPIII are considered as highly
tissue-specific and moderately sensitive markers for pri-
mary and metastatic urothelial cancers, metastatic cancer
of unknown primary origin, and markers that differenti-
ate primary carcinoma of the urothelium from other
cancers of the genitourinary system [5, 10, 59,
99–110]. UPIII is also considered as valuable and sen-
sitive marker appearing in urine in association with
bladder cancer [108]. However, none of the research
team analyzed the alterations in the expression/s of
glycotope/s on UPs in relation to cancer of the bladder
and/or urinary tract. Future studies and insight into UP
glycoforms as differential diagnostic and early indicators
of urotelial cancer should be encouraged.
Besides the diagnostic usage for glycovariants of
UPs, studies of their glycoconjugates carry important
applications in the future for development of targeted
drugs through lectins. A specific structure of oligosac-
charide moieties of the urothelium glycoconjugates has
been tested for improved intravesical drug delivery in
cancer therapy [111, 112]. The idea of glycotargets
approach of Neutsch et al. [111, 112] is based on a
molecular efficient cytoinvasion of uropathogenic bacte-
ria, mediated via a mannose-directed FimH adhesin, and
malignancy-dependent differences in bladder cell glyco-
sylation. Their carrier-based delivery concept, combines
biorecognitive targeting using plant lectin wheat germ
agglutinin (WGA) immobilized on poly(lactide-co-
glycolide) microparticles for steady cytoadhesion. Sev-
eral DNA-selective chemotherapeutics with established
track record in uro-oncology for physicochemical com-
patibility with the polymeric carrier formulation have
been tested and the preliminary data are promising.
The results of this work show potential in glycotargeted
deliveries in the intravesical setting and offer new per-
spectives for the application of lectin-based drugs in the
urinary tract malfunctions [112]. However, progress on
drug delivery systems tailored to the penetration-hostile
urothelial barrier lags behind the advancements in com-
parable fields.
Conclusions and future prospects
Particularly fascinating and newly discovered aspect of
uroplakin biology and thus the biology and physiology of the
urothelium are uroplakin glycovariants. It seems that an in-depth
knowledge of the molecular pathogenesis of glycosylation, for-
mation of microheterogenic glycoforms, products of their me-
tabolism and degradation may set new directions for future
research. Some of glycotopes terminated by sialic acid and/or
fucose as tumor markers could potentially be used to detect
tumors in asymptomatic patients, especially at high risk or
monitoring of recurrence after treatment of the primary tumor.
Besides of diagnostic usage, the glycoconjugates can carry
important applications in lectin-mediated drug delivery [16].
Blood- urine barrier which forms the urothelium is one of the
least permeable membranes of the body and is also a challenge
to the penetration of drugs. Studies by Kreft et al. showed that
the WGA lectin binds to and is endocytosed by umbrella cells
at hinge regions, a potential entry for biopharmaceuticals
[113, 114]. The use of lectins recognizing the sugar residues
at this particular region can be very effective and valuable in
construction of targeted therapies and the treatment of infec-
tious diseases, cancer and IC of the urinary system. Such
selective delivery of the active ingredient (drug) directly to
urothelium allows targeted treatment without creation of ab-
errant cell damage to healthy tissues.
There is no doubt that glycosylation of UPs is closely
related to UPs function and its malfunction is a reflection of
the ongoing pathological process. Due to the fact that changes
in the glycosylation of UPs are primary to the underlying
changes in relation to the overall expression of the UP, their
early detection may help to capture lesions in their early
stages. Since urine analysis has a number of advantages,
including the availability of large quantities of the material
and noninvasive sampling, testing glycobiomarkers in urine is
highly desirable [115]. In order to evaluate and validate the
clinical utility of UPs glycoforms, their variable molecular
native forms and/or possibly degraded, mannosylated versus
sialylated and fucosylated glycovariants, further studies on the
large scale and the involvement of multidisciplinary research
teams are needed.
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